Recurrent and Primary Refractory Ewing Sarcoma
Conditions
Brief summary
Event-free survival time (EFS)
Detailed description
Objective imaging response (OR) according to RECIST 1.1 criteria after 2, 4, and 6 cycles for CE and after 2 and 4 cycles for IFOS and IFOS-L, and at the end of trial treatment for all arms, Progression-free survival time (PFS), Overall survival time (OS), Toxicity, defined by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v4.0 (see Appendix 2 of protocol), PET-CT response after 4 cycles, Quality of life (QoL), Days spent in hospital
Interventions
DRUGGEMCITABINE
DRUGTEMOZOLOMIDE
DRUGIFOSFAMIDE
DRUGCARBOPLATIN
DRUGETOPOSIDE PHOSPHATE
DRUGDOCETAXEL
DRUGIRINOTECAN
DRUGCYCLOPHOSPHAMIDE
DRUGTOPOTECAN
DRUGETOPOSIDE
Sponsors
The University Of Birmingham
Eligibility
Sex/Gender
All
Age
0 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Event-free survival time (EFS) | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective imaging response (OR) according to RECIST 1.1 criteria after 2, 4, and 6 cycles for CE and after 2 and 4 cycles for IFOS and IFOS-L, and at the end of trial treatment for all arms, Progression-free survival time (PFS), Overall survival time (OS), Toxicity, defined by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v4.0 (see Appendix 2 of protocol), PET-CT response after 4 cycles, Quality of life (QoL), Days spent in hospital | — |
Countries
Austria, Belgium, Czechia, Denmark, Finland, France, Italy, Netherlands, Norway, Spain
Outcome results
None listed